Lifestyle
- regular physical activity
- stress management
- adequate sleep
Interleukin-6 · Interleukin 6
IL-6 quantifies the level of interleukin-6, a cytokine involved in inflammatory and immune responses.
Levels may vary based on age, sex, and health status. Fasting is not required.
Interleukin-6 (IL-6) is a multifunctional cytokine involved in the regulation of immune responses, inflammation, and hematopoiesis. It is produced by various cell types, including leukocytes, adipocytes, and endothelial cells, and plays a crucial role in the acute phase response. IL-6 signaling is mediated through a complex involving the IL-6 receptor and the signal transducer gp130, leading to the activation of downstream pathways that influence immune cell differentiation and proliferation. Clinically, IL-6 is a significant biomarker for inflammatory conditions and is implicated in the pathogenesis of cardiovascular diseases, such as atherosclerosis and cardiogenic shock, as well as neurological disorders like epilepsy. Elevated IL-6 levels are associated with increased risk of heart failure, atrial fibrillation, and other cardiac complications. In the context of athletic performance and biohacking, IL-6 is of interest due to its role in muscle repair and adaptation to exercise, although chronic elevation may indicate overtraining or systemic inflammation. Researchers observed that IL-6 levels can be influenced by various factors, including time of day, stress, and recent physical activity, which should be considered when interpreting test results. Confounding factors such as acute infections or chronic inflammatory conditions can also affect IL-6 levels, making it essential to evaluate this marker in conjunction with other clinical findings.
Klinische Bedeutung
Elevated IL-6 levels indicate systemic inflammation and are associated with increased risk of cardiovascular diseases, infections, and certain cancers. Low IL-6 levels are generally not of clinical concern but may indicate immunosuppression.
Progressively rising IL-6 levels suggest worsening inflammation or disease progression. Retest in 4 weeks if elevated.
Falling IL-6 levels indicate a reduction in inflammatory activity or effective treatment response.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen.
IL-6 levels may vary throughout the day; morning samples are preferred for consistency.
Testing Frequency
As needed based on clinical symptoms or chronic disease management.
Correlated with
Current research suggests that the perioperative kinetics of IL-6 in cardiac surgical patients remain insufficiently elaborated, with unclear influencing factors and clinical implications. Researchers have not yet established optimal reference ranges or the impact of confounders on IL-6 levels across various conditions. Additionally, clinical questions regarding the efficacy of IL-6-targeted therapies in cardiogenic shock and the specific mechanisms linking IL-6 to neuropsychiatric comorbidities in epilepsy remain unanswered.
853
Total Citations
5
Human/RCT
5.0
Avg. Influence
2025
Latest
Researchers found that IL-6 plays a significant role in cardiovascular disease, linking it to vascular risk and atherogenesis. The study highlights the potential of IL-6 inhibition as a therapeutic approach for various cardiovascular conditions. Additionally, it discusses the development of ziltivekimab, an IL-6 ligand inhibitor, for high-risk patients.
Researchers found that C-reactive protein (CRP) is a widely used biomarker for inflammation, synthesized in response to cytokines like IL-6. The study emphasizes the increasing demand for CRP testing in clinical laboratories due to its sensitivity in diagnosing various inflammatory conditions. It also highlights the renewed interest in CRP as a marker for COVID-19 severity.
This review focused on the role of interleukin-6 (IL-6) in Castleman disease, particularly its hyperfunction in the plasma cell variant. Researchers found that symptoms of multicentric Castleman disease improve with anti-IL-6 treatments, indicating IL-6's key role in the disease's pathogenesis. The findings underscore the therapeutic potential of targeting IL-6 in managing this condition.
Researchers summarized the role of IL-6 in neurodegenerative disorders, noting its involvement in neuroinflammation and potential as a biomarker for disease progression. The study emphasizes the need for further exploration of IL-6's clinical applications in these conditions.
This study investigated the relationship between lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6) in the context of atherosclerotic cardiovascular disease (ASCVD). Researchers found that IL-6 receptor inhibitors can lower Lp(a) levels and may have dual effects on inflammation and apolipoprotein synthesis, suggesting potential benefits in ASCVD prevention. The study calls for more trials to clarify these interactions.
Researchers found that IL-6 plays a critical role in the pathophysiology of ischemic stroke, acting as a pro-inflammatory mediator during the acute phase. The study highlights IL-6's potential as a prognostic factor in stroke severity and patient outcomes.
This review explored the role of interleukin-6 (IL-6) in rheumatoid arthritis (RA) treatment. Researchers found that IL-6 inhibition shows superior efficacy compared to placebo and traditional therapies, with a comparable safety profile to TNF inhibitors. The findings highlight the importance of targeting IL-6 in managing RA.
This study focused on the immunopathogenesis of neuromyelitis optica (NMO) and the role of interleukin-6 (IL-6) receptor signaling in its treatment. Researchers found that therapies targeting IL-6 receptor are effective in preventing NMO relapses, suggesting IL-6 as a potential biomarker for treatment responsiveness. The findings support a precision medicine approach in NMO management.
Researchers observed that IL-6 is a reliable biomarker for cardiac dysfunction and related complications in patients undergoing cardiac operations. The study discusses the need for further investigation into the perioperative dynamics of IL-6 and its impact on clinical outcomes in cardiac surgery.
This review examined the role of interleukin-6 (IL-6) in atherosclerosis and its association with cardiovascular risk. Researchers found that high IL-6 levels are linked to increased cardiovascular risk and that targeting IL-6 may help manage atherosclerosis progression. The study emphasizes the need for further research into IL-6 as a biomarker of residual inflammatory risk.
Research publications about IL-6 over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer